Regulatory
Novartis’ Cosentyx (secukinumab) Receives EC’s Approval for Axial Spondyloarthritis Spectrum
Shots: The approval is based on P-III PREVENT study involve assessing Cosentyx (150mg, SC with loading dose and 150mg with no loading dose) vs PBO in 555 adult patients with active nr-axSpA (with onset before 45yrs. of age, spinal pain rated as >=40/100 on a VAS and BASDAI >=4), who had treated with at least […]Read More
